Asset
ARAMCHOL MEGLUMINE
GALMED PHARMACEUTICALS LTD. ORDINARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02279524 | phase2 | completed | 2015-04-29 | 2018-05-22 | Galmed Research and Development, Ltd. | A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH |
| NCT00776841 | phase1 | completed | 2008-09-01 | 2009-09-01 | Galmed Medical Reserch | A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers |
| NCT06095986 | phase2 | withdrawn | 2025-06-01 | 2026-09-01 | Galmed Pharmaceuticals Ltd | A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis |
| NCT05874336 | phase1 | completed | 2020-06-17 | 2020-08-11 | Galmed Pharmaceuticals Ltd | An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol |
| NCT06502561 | phase1 | completed | 2025-02-15 | 2025-06-15 | Galmed Pharmaceuticals Ltd | Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets |
FDA applications (0)
This company has no applications containing this asset.